Yo-Yo dieting without additional treatment can explain high placebo response rates in NASH clinical trials
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
New RENAsym platform helps drug developers avoid kidney injury side effects
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym...
Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products
Collaboration will combine novel experimental techniques and mechanistic modeling strategies
Simulations Plus Reports Fourth Quarter and Full Year Fiscal 2021 Results
Fiscal 2021 revenue increased 12% year-over-year to $46.5 million
Software revenue increased 28% year-over-year to $27.7 million
Fiscal 2022 financial outlook for total revenue of $51 million to $53 million, reflecting 10% to 15% year-over-year growth
Simulations Plus Announces the University+ Program
Free access to Simulations Plus software for accredited universities will accelerate learning and educational pursuits
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call
Conference Call to be on Monday, October 25, 2021, at 5:00 PM ET
Simulations Plus Receives New Grant Award From the FDA
Improvements to the GastroPlus® platform will increase its impact in driving research and regulatory decisions on dermatological products
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be...
Simulations Plus Reports Continued Success in Second Phase of AIDD Collaboration with Large Pharmaceutical Company
30% of synthesized molecules have measured activity which meet potency targets.
NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®
Simulations Plus announced that China's Center for Drug Evaluation of the NMPA has added GastroPlus licenses for research aiding regulatory reviews
Simulations Plus Celebrates 25 Years in Business
Continuing the commitment to improve public health through innovative solutions
Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call
Conference call to be on Monday, July 12, 2021, at 4:15 p.m. ET
Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Idiopathic Pulmonary Fibrosis (IPF)
IPFsym will enable new software and services revenue by aiding development of IPF therapies
Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus Uplisted to The Nasdaq Global Select Market®
Strong growth, innovation, and global reach drive the company’s progress
Simulations Plus Releases ADMET Predictor® (X.2)
Industry-driven enhancements further establish ADMET Predictor® as the preferred platform for discovery PBPK simulations